Drag a card by its title · ⚙ to size, swap or remove

The company

Relay Therapeutics, Inc.

RLAY · Nasdaq

Health CareBiotechnologyJust started moving

RLAY stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 11.9% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation: Just started moving
Weeks in an uptrend: 52 in a row
Industry in uptrend: 18% -14 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $258.1M
Officials’ trades on record: 4
Institutions holding: 247 (+12)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.

21 Apr – 20 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

4 disclosed lines: House 1, Senate 0, executive 3; 2 people.

Who	Did	Amount	Traded
Daniel S. Goldman House: U.S. House ClerkNY10	sold	$1k–$15k	12 Jul 2023filed 13 Aug 2023
Eric S. Lander Executive branch: Office of Government EthicsOffice of Science and Technology Policy	sold	$50k–$100k	11 Jun 2021filed 8 Sep 2021
Eric S. Lander Executive branch: Office of Government EthicsOffice of Science and Technology Policy	sold	$50k–$100k	11 Jun 2021filed 8 Sep 2021
Eric S. Lander Executive branch: Office of Government EthicsOffice of Science and Technology Policy	sold	$100k–$250k	10 Jun 2021filed 8 Sep 2021

Insiders

Buy orders, 12 months0

Sale orders, 12 months38

Buyers · sellers0 · 6

Who	Did	Shares	Traded
Sanjiv PatelPresident and CEO	sold	48,199at $18.10	7 Oct 2026filed 8 Oct 2026
Thomas CatinazzoChief Financial Officer	sold	17,511at $18.58	6 Oct 2026filed 8 Oct 2026
Thomas CatinazzoChief Financial Officer	sold	206at $19.26	6 Oct 2026filed 8 Oct 2026
Sanjiv PatelPresident and CEO	sold	48,199at $18.94	8 Sep 2026filed 9 Sep 2026
Thomas CatinazzoChief Financial Officer	sold	17,717at $18.94	8 Sep 2026filed 9 Sep 2026
Donald A. BergstromPresident, R&D	sold	8,530at $18.97	8 Sep 2026filed 9 Sep 2026
Peter RahmerSee remarks	sold	4,508at $20.03	26 Aug 2026filed 28 Aug 2026
Svf Pauling (Cayman) Ltd10% owner	sold	6,000,000at $19.40	25 Aug 2026filed 28 Aug 2026
Sanjiv PatelPresident and CEO	sold	48,199at $20.33	17 Aug 2026filed 18 Aug 2026
Thomas CatinazzoChief Financial Officer	sold	17,717at $19.74	14 Aug 2026filed 18 Aug 2026
Donald A. BergstromPresident, R&D	sold	2,237at $18.61	28 Jul 2026filed 30 Jul 2026
Peter RahmerSee remarks	sold	748at $18.61	28 Jul 2026filed 30 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders247+12 on the quarter

New · exited47 · 34

Reported value$4.4B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
SB INVESTMENT ADVISERS (UK) LTDunchanged · filed 14 Aug 2026	27,904,963$522.1M	00.0%
FMR LLCadded · filed 13 Aug 2026	20,110,113$376.3M	+16,414,682+444.2%
Casdin Capital, LLCadded · filed 14 Aug 2026	16,035,240$300.0M	+1,616,666+11.2%
BlackRock, Inc.added · filed 7 Aug 2026	15,288,260$286.0M	+2,312,903+17.8%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 2026	14,544,658$265.1M	+4,793,517+49.2%
Commodore Capital LPreduced · filed 14 Aug 2026	12,000,000$224.5M	-5,000,000−29.4%
STATE STREET CORPadded · filed 7 Aug 2026	10,125,381$189.5M	+3,891,836+62.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	8,984,284$167.8M	+1,576,958+21.3%
Nextech Invest Ltd.added · filed 14 Aug 2026	6,776,506$126.8M	+1,250,000+22.6%
Bellevue Group AGreduced · filed 14 Aug 2026	6,185,970$115.7M	-1,609,272−20.6%